Sign in Subscribe

GLP-1

A collection of 3 issues

Retatrutide: The Triple Agonist That Could Redefine Weight Loss

retatrutide-the-triple-agonist-that-could-redefine-weight-loss">Retatrutide: The Triple Agonist That Could Redefine Weight Loss Key Takeaways - Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously - Phase 2 trials showed up to 24.2% weight loss at 48 weeks with 12mg weekly dosing - Currently investigational — not approved

Tirzepatide: The Dual GIP/GLP-1 Agonist Revolutionizing Weight Management

Tirzepatide: The Dual GIP/GLP-1 Agonist Revolutionizing Weight Management Key Takeaways - Tirzepatide is the first dual GIP/GLP-1 receptor agonist, targeting two incretin pathways simultaneously - Clinical trials show 15-22% weight loss over 72 weeks, superior to single GLP-1 agonists - FDA-approved as Mounjaro for diabetes and Zepbound for

Semaglutide: The Science Behind the GLP-1 Revolution

semaglutide-the-science-behind-the-glp-1-revolution">Semaglutide: The Science Behind the GLP-1 Revolution Key Takeaways - Semaglutide mimics GLP-1 hormone, slowing gastric emptying and reducing appetite through central nervous system pathways - Clinical trials show 15-20% body weight reduction in non-diabetic adults at 2.4mg weekly doses - Common side effects include nausea